Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 104

1.

Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.

Molavi O, Xiong XB, Douglas D, Kneteman N, Nagata S, Pastan I, Chu Q, Lavasanifar A, Lai R.

Biomaterials. 2013 Nov;34(34):8718-25. doi: 10.1016/j.biomaterials.2013.07.068. Epub 2013 Aug 12.

PMID:
23942212
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Effective therapy for a murine model of human anaplastic large-cell lymphoma with the anti-CD30 monoclonal antibody, HeFi-1, does not require activating Fc receptors.

Zhang M, Yao Z, Zhang Z, Garmestani K, Goldman CK, Ravetch JV, Janik J, Brechbiel MW, Waldmann TA.

Blood. 2006 Jul 15;108(2):705-10. Epub 2006 Mar 21.

PMID:
16551968
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.

Pasqualucci L, Wasik M, Teicher BA, Flenghi L, Bolognesi A, Stirpe F, Polito L, Falini B, Kadin ME.

Blood. 1995 Apr 15;85(8):2139-46.

PMID:
7718885
[PubMed - indexed for MEDLINE]
Free Article
4.

A murine xenograft model for human CD30+ anaplastic large cell lymphoma. Successful growth inhibition with an anti-CD30 antibody (HeFi-1).

Pfeifer W, Levi E, Petrogiannis-Haliotis T, Lehmann L, Wang Z, Kadin ME.

Am J Pathol. 1999 Oct;155(4):1353-9.

PMID:
10514417
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) that grows in SCID-mice with the morphologic features of a CD30+ anaplastic large cell lymphoma, and is sensitive to anti-CD30 immunotoxins.

Tazzari PL, de Totero D, Bolognesi A, Testoni N, Pileri S, Roncella S, Reato G, Stein H, Gobbi M, Stirpe F.

Haematologica. 1999 Nov;84(11):988-95.

PMID:
10553158
[PubMed - indexed for MEDLINE]
Free Article
6.

In vivo antitumor effects of unconjugated CD30 monoclonal antibodies on human anaplastic large-cell lymphoma xenografts.

Tian ZG, Longo DL, Funakoshi S, Asai O, Ferris DK, Widmer M, Murphy WJ.

Cancer Res. 1995 Nov 15;55(22):5335-41.

PMID:
7585597
[PubMed - indexed for MEDLINE]
Free Article
7.

Targeting CD30 in anaplastic large cell lymphoma.

Vadakara J, Pro B.

Curr Hematol Malig Rep. 2012 Dec;7(4):285-91. doi: 10.1007/s11899-012-0137-y. Review.

PMID:
23065407
[PubMed - indexed for MEDLINE]
8.

The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma.

Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O, Zhang HF, Davis T, Keler T, Diehl V, Graziano RF, Engert A.

Blood. 2003 Nov 15;102(10):3737-42. Epub 2003 Jul 24.

PMID:
12881320
[PubMed - indexed for MEDLINE]
Free Article
9.

Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice.

Gupta B, Torchilin VP.

Cancer Immunol Immunother. 2007 Aug;56(8):1215-23. Epub 2007 Jan 12.

PMID:
17219149
[PubMed - indexed for MEDLINE]
10.

Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma.

Shehan JM, Kalaaji AN, Markovic SN, Ahmed I.

J Am Acad Dermatol. 2004 Jul;51(1):103-10. Review.

PMID:
15243534
[PubMed - indexed for MEDLINE]
11.

Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.

ElBayoumi TA, Torchilin VP.

Clin Cancer Res. 2009 Mar 15;15(6):1973-80. doi: 10.1158/1078-0432.CCR-08-2392. Epub 2009 Mar 10.

PMID:
19276264
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice.

Elbayoumi TA, Torchilin VP.

Mol Pharm. 2009 Jan-Feb;6(1):246-54. doi: 10.1021/mp8001528.

PMID:
19049322
[PubMed - indexed for MEDLINE]
Free PMC Article
13.
14.

Dose dependency of pharmacokinetics and therapeutic efficacy of pegylated liposomal doxorubicin (DOXIL) in murine models.

Gabizon A, Tzemach D, Mak L, Bronstein M, Horowitz AT.

J Drug Target. 2002 Nov;10(7):539-48.

PMID:
12683721
[PubMed - indexed for MEDLINE]
15.

Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes.

Sapra P, Allen TM.

Clin Cancer Res. 2004 Apr 1;10(7):2530-7. Erratum in: Clin Cancer Res. 2004 Jul 15;10(14);4893.

PMID:
15073133
[PubMed - indexed for MEDLINE]
Free Article
16.

Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.

Terenzi A, Bolognesi A, Pasqualucci L, Flenghi L, Pileri S, Stein H, Kadin M, Bigerna B, Polito L, Tazzari PL, Martelli MF, Stirpe F, Falini B.

Br J Haematol. 1996 Mar;92(4):872-9.

PMID:
8616080
[PubMed - indexed for MEDLINE]
17.

Pharmacokinetics, efficacy and toxicity of different pegylated liposomal doxorubicin formulations in preclinical models: is a conventional bioequivalence approach sufficient to ensure therapeutic equivalence of pegylated liposomal doxorubicin products?

Mamidi RN, Weng S, Stellar S, Wang C, Yu N, Huang T, Tonelli AP, Kelley MF, Angiuoli A, Fung MC.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1173-84. doi: 10.1007/s00280-010-1406-x. Epub 2010 Jul 27.

PMID:
20661737
[PubMed - indexed for MEDLINE]
18.

Efficacy, biodistribution, and pharmacokinetics of CD22-targeted pegylated liposomal doxorubicin in a B-cell non-Hodgkin's lymphoma xenograft mouse model.

Tuscano JM, Martin SM, Ma Y, Zamboni W, O'Donnell RT.

Clin Cancer Res. 2010 May 15;16(10):2760-8. doi: 10.1158/1078-0432.CCR-09-3199. Epub 2010 May 11.

PMID:
20460479
[PubMed - indexed for MEDLINE]
Free Article
19.

Enhanced tumor delivery and antitumor activity in vivo of liposomal doxorubicin modified with MCF-7-specific phage fusion protein.

Wang T, Hartner WC, Gillespie JW, Praveen KP, Yang S, Mei LA, Petrenko VA, Torchilin VP.

Nanomedicine. 2014 Feb;10(2):421-30. doi: 10.1016/j.nano.2013.08.009. Epub 2013 Sep 9.

PMID:
24028893
[PubMed - indexed for MEDLINE]
20.

Combination of the human anti-CD30 antibody 5F11 with cytostatic drugs enhances its antitumor activity against Hodgkin and anaplastic large cell lymphoma cell lines.

Heuck F, Ellermann J, Borchmann P, Rothe A, Hansen H, Engert A, von Strandmann EP.

J Immunother. 2004 Sep-Oct;27(5):347-53.

PMID:
15314543
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk